All studies
Immunology · Registry · UK, Ireland

Yiu 2021

Psoriasis

PPSuperiorityAcademic2/5 disclosures
Comparisons
2
In the analysis
0
2 withheld
Target trials
1
Emulations reported
5
2 treatments

Comparisons

2 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
PASI 90 (≥ 90% improvement in PASI)
vs CLEAR·RR·Efficacy
1.241.11–1.37
1.271.04–1.56
not pooled
PASI ≤ 2 after 12 months
vs CLEAR·RR·Efficacy
1.241.11–1.37
1.281.06–1.55
not pooled

Design and methods

Estimand
PP
Design hypothesis
Superiority
Matching / weighting
1:1 PS matching, IPTW
Analysis method
Generalized linear models with a log link (RR), with an identity link (RD)
Missing data
Complete case, Nonresponder imputation, LOCF, IPCW, Multiple imputation
Covariates adjusted
18
DAG
No
QBA
No

Data and sample

Data type
Registry
Data sources
1
Geography
UK, Ireland
Eligible sample
1231
Treated
314
Control
917
Emulations
5
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Samsung Bioepis, Sandoz Hexal AG, UCB Pharma Ltd
Funding
Declared: Public, professional society, private
Funders
NIHR Manchester Biomedical Research Centre, NIHR Newcastle Biomedical Research Centre

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2021_Yiu_Psoriasis
DOI
https://doi.org/10.1001/jamadermatol.2020.4202
Affiliations
University of Manchester, Newcastle University Medical School, Newcastle Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Salford Royal NHS Foundation Trust
Sector
Academic
Target trials (study level)
CLEAR
Registration
NCT02074982